The Plasma Proteins Market in the United States – 2015 report, published annually since 1977, is a comprehensive market analysis of the therapeutic plasma and recombinant proteins sold in the U.S. in 2015.  It provides sales data and historical trends, in units, dollars and market shares by company.  Regulatory, economic and health care issues affecting the market are also discussed. This report is updated every year.

The report is delivered electronically (Excel and pdf files) and as a hard copy. Individual sections of the report may be purchased separately. For more information or to order this report, please contact The Marketing Research Bureau at mrb_ibpn@earthlink.net, or +1 203 799-0298.

 


 

THE PLASMA PROTEINS MARKET
IN THE UNITED STATES — 2015

 

TABLE OF CONTENTS

Page

 

 

1

 

13

14

22

24

 

44

44

47

48

48

 

63

63

 

63

63

63

64

64

64

64

65

65

65

65

65

65

66

66

67

67

68

70

78

 

84

 

85

97

97

101

105

106

108

112

115

 

116

116

116

120

121

122

123

124

129

 

140

140

141

142

 

147

148

153

157

160

173

175

184

192

 

194

 

203

 

208

208

211

211

 

213

213

215

 

218

218

229

 

231

 

231

 

232

 

241

 

243

 

245

 

254

 

255

 

262

 

266

 

 

 

EXECUTIVE SUMMARY

 

1) PLASMA COLLECTIONS

1.1) The Plasma Collection Sector

1.2) Source Plasma Safety

1.3) Major Plasma Collection Organizations

 

2) PLASMA FRACTIONATION

2.1)   Processing Capacity and Throughput

2.2)   Fractionation Plant Expansions

2.3)   Fractionation Production Cycle

2.5)   Production Yields

 

3) MARKET OVERVIEW

3.1)      The Plasma Proteins Market by Product

3.1.1)      Polyvalent Intravenous and Subcutaneous Immune Globulin IVIG/SCIG

3.1.2)      Albumin and Plasma Protein Fraction (PPF)

3.1.3)      Factor VIII and von Willebrand Factor

3.1.4)      Factor IX

3.1.5)      Prothrombin Complex Concentrates (PCC)

3.1.6)      Inhibitor Products (Factor VIII/IX Bypassing Agents)

3.1.7)      Fibrinogen

3.1.8)      Factor XIII

3.1.9)      Alpha 1 Antitrypsin

3.1.10)    C-1 Esterase Inhibitor

3.1.11)    Antithrombin III

3.1.12)    Fibrin Sealant

3.1.13)    Thrombin

3.1.14)    Protein C

3.1.15)    Hyperimmune Globulin Products

3.2)      Pricing Trends

3.3)      Product Mix

3.4)      The Plasma Fractions Market by Company

3.5)      Historical Development

3.6)      Recent Products Approvals

 

4) IMMUNE GLOBULIN MARKET

4.1)   Intramuscular Polyvalent Immune Globulin Market and Hyperimmune Globulin

4.2)   Polyvalent Intravenous Immune Globulin Market (IVIG)

4.2.1)         Polyvalent Intravenous Immune Globulin (IVIG) History

4.2.2)         Subcutaneous Immune Globulin (SCIG)

4.2.3)         Clinical Use of IVIG/SCIG

4.2.4)         Market Development

4.2.5)         Results by Company

4.2.6)         IV/SCIG Pricing and Reimbursement

4.2.7)         IV/SCIG Distribution

 

5) ALBUMIN MARKET

5.1)      History of Albumin

5.2)      Clinical Use of Albumin

5.3)      Colloids vs. Crystalloids

5.4)      The 1998 Cochrane Review, the 2004 SAFE Study

5.5)      Non-Therapeutic Use of Albumin and Recombinant Albumin

5.6)      Therapeutic Apheresis Market

5.7)      Market Development

5.8)      Clinical Studies on Albumin

 

6) HEMOPHILIA CARE MARKET

6.1)      Introduction

6.2)      Historical Development

6.3)      Hemophilia Patient Population

6.4)      Hemophilia Treatment Centers, Specialty Pharmacies and Home Care

6.5)      Historical review of coagulation factors development

6.6)      Clinical Development of New Hemophilia Treatments

6.7)      Factor VIII Market

6.8)      Factor IX Market

6.9)      Von Willebrand Disease Market

6.10)    Prothrombin  Complex Market

6.11)    Inhibitor Agents Market

6.12)    Other Bleeding Disorders

 

7) ALPHA-ONE ANTITRYPSIN MARKET

 

8) C-1 ESTERASE INHIBITOR MARKET

 

9) FIBRIN SEALANT MARKET

9.1)      Fibrin Sealant Market

9.2)      Thrombin Market

9.3)      Other Tissue Sealing Products and Technologies

 

10) OTHER PLASMA PRODUCTS

10.1)    Protein C

10.2)    Antithrombin III

 

11) DISTRIBUTION OF PLASMA PRODUCTS

11.1)    Overview

11.2)    Specialty Pharmacies & Home Care

 

12) PROFILES  OF THE MAJOR FRACTIONATORS IN THE US

 

12.1) BIO PRODUCTS LABORATORY (BPL)

 

12.2) BAXALTA/SHIRE

 

12.3) BAYER HEALTHCARE

 

12.4) BIOTEST BIOPHARMACEUTICALS

 

12.5) CSL BEHRING

 

12.6) EMERGENT BIOSOLUTIONS

 

12.7) GRIFOLS

 

12.8) KEDRION BIOPHARMA

 

12.9) OCTAPHARMA